See more : Dover Corporation (DOV) Income Statement Analysis – Financial Results
Complete financial analysis of Petros Pharmaceuticals, Inc. (PTPI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Petros Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Veoneer, Inc. (VNE) Income Statement Analysis – Financial Results
- NuTech Energy Resources, Inc. (NERG) Income Statement Analysis – Financial Results
- Automobile Corporation of Goa Limited (ACGL.BO) Income Statement Analysis – Financial Results
- Lets Holdings Group Co., Ltd. (002398.SZ) Income Statement Analysis – Financial Results
- GeeCee Ventures Limited (GEECEE.BO) Income Statement Analysis – Financial Results
Petros Pharmaceuticals, Inc. (PTPI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.petrospharma.com
About Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 5.82M | 5.99M | 7.81M | 9.56M | 15.58M | 14.05M |
| Cost of Revenue | 1.63M | 2.29M | 1.60M | 4.05M | 7.43M | 10.48M |
| Gross Profit | 4.19M | 3.70M | 6.21M | 5.51M | 8.15M | 3.57M |
| Gross Profit Ratio | 71.98% | 61.79% | 79.52% | 57.67% | 52.32% | 25.41% |
| Research & Development | 2.41M | 1.74M | 1.79M | 459.64K | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.26M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -41.15K |
| SG&A | 9.26M | 12.21M | 15.59M | 15.67M | 19.73M | 11.22M |
| Other Expenses | 6.14M | 5.60M | 6.88M | 6.66M | 5.29M | 0.00 |
| Operating Expenses | 17.81M | 19.55M | 24.26M | 22.80M | 25.02M | 11.22M |
| Cost & Expenses | 19.44M | 21.84M | 25.86M | 26.84M | 32.45M | 21.70M |
| Interest Income | 515.31K | 14.19K | 368.66K | 3.05M | 13.84M | 11.86M |
| Interest Expense | 536.14K | 596.02K | 368.66K | 3.05M | 13.84M | 0.00 |
| Depreciation & Amortization | 3.42M | 5.72M | 6.98M | 6.75M | 5.32M | 8.06M |
| EBITDA | -4.21M | -13.73M | -1.64M | -12.21M | -14.00M | 373.58K |
| EBITDA Ratio | -72.34% | -114.20% | -143.00% | -111.11% | -74.32% | 2.95% |
| Operating Income | -13.62M | -15.85M | -18.05M | -17.28M | -16.87M | -7.65M |
| Operating Income Ratio | -233.88% | -264.45% | -231.05% | -180.78% | -108.29% | -54.45% |
| Total Other Income/Expenses | 5.45M | -121.82K | 9.06M | -4.73M | -13.84M | -24.84M |
| Income Before Tax | -8.16M | -20.04M | -8.99M | -22.01M | -33.16M | -32.49M |
| Income Before Tax Ratio | -140.20% | -334.40% | -115.05% | -230.27% | -212.86% | -231.20% |
| Income Tax Expense | 0.00 | 7.00M | 368.66K | -1.43M | -645.87K | -13.37K |
| Net Income | -8.16M | -27.04M | -9.36M | -20.59M | -32.51M | -32.47M |
| Net Income Ratio | -140.20% | -451.22% | -119.77% | -215.35% | -208.71% | -231.10% |
| EPS | -6.35 | -13.06 | -8.59 | -21.21 | -190.46 | -324.73 |
| EPS Diluted | -6.35 | -13.06 | -8.59 | -21.21 | -190.46 | -324.73 |
| Weighted Avg Shares Out | 2.18M | 2.07M | 1.09M | 970.77K | 170.70K | 100.00K |
| Weighted Avg Shares Out (Dil) | 2.18M | 2.07M | 1.09M | 970.77K | 170.70K | 100.00K |
PTPI Stock: 11 Things to Know About Penny Stock Petros Pharmaceuticals as Shares Rocket 100%+
Petros Pharmaceuticals (PTPI) stock is surging higher on Tuesday following a filing with the U.S. Securities and Exchange Commission (SEC). The post PTPI Stock: 11 Things to Know About Penny Stock Petros Pharmaceuticals as Shares Rocket 100%+ appeared first on...
Petros Pharmaceuticals (PTPI) Stock: Why The Price Surged Today
The stock price of Petros Pharmaceuticals Inc (NASDAQ: PTPI) increased by over 190% pre-market today. This is why it happened.
Petros Pharmaceuticals to Present at the Q4 Investor Summit Conference
NEW YORK, Nov. 11, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Q4 Investor Summit Conference, which...
Hot Penny Stocks to Watch as AMC and GME Go to the Moon
Which penny stocks are you watching as GME stock and AMC stock shoot toward the moon? The post Hot Penny Stocks to Watch as AMC and GME Go to the Moon appeared first on Penny Stocks to Buy, Picks, News...
Petros Pharmaceuticals (PTPI) Stock: Why The Price Surged Today
The stock price of Petros Pharmaceuticals Inc (NASDAQ: PTPI) increased by over 90% during intraday trading today. This is why it happened.
Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering
NEW YORK, Oct. 19, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced the closing of its previously announced registered direct offering with the company's largest and other existing investors for gross proceeds of...
Petros Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
NEW YORK, Sept. 10, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will present at the H.C.
Petros Pharmaceuticals Announces Second Quarter Financial Results and Provides Corporate Update; Reports a 123% Increase in Year Over Year Quarterly STENDRA® (avanafil) Net Sales
NEW YORK, Aug. 17, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced financial results for the second quarter ended June 30, 2021. Second Quarter Highlights: Completed pilot...
Petros Pharmaceuticals: Invitation to the Q3 Virtual Investor Summit
New Jersey and Pennsylvania--(Newsfile Corp. - August 11, 2021) - Petros Pharmaceuticals (NASDAQ: PTPI) today announced that Fady Boctor, President, Chief Commercial Officer will be attending the Q3 Virtual Investor Summit. Event Q3 Investor Summit Date August 17-18th, 2021 Presentation August 17th at 12:30 PM ET
Petros Pharmaceuticals to Present at the Access to Giving Virtual Investor Conference on July 14, 2021
NEW YORK, July 12, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Access to Giving Virtual...
Source: https://incomestatements.info
Category: Stock Reports